The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines

[1]  E. Bosmans,et al.  The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. , 1998, Journal of affective disorders.

[2]  J. Born,et al.  Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. , 1998, The Journal of clinical endocrinology and metabolism.

[3]  M. Fujimoto,et al.  Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. , 1998, The Journal of rheumatology.

[4]  S. Horiuchi,et al.  Elevated Serum Levels of the Soluble Form of gp130, the IL‐6 Signal Transducer, in HTLV‐1 Infection and No Involvement of Alternative Splicing for Its Generation , 1998, Microbiology and immunology.

[5]  V. Poli,et al.  Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. , 1997, Cytokine.

[6]  A. Malhotra,et al.  Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[7]  H. Kiyama,et al.  Accelerated Nerve Regeneration in Mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma , 1996, The Journal of experimental medicine.

[8]  H. Pope,et al.  The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. , 1996, The Psychiatric clinics of North America.

[9]  Reiffenberger Dh,et al.  Fibromyalgia syndrome: a review. , 1996, American family physician.

[10]  E. Wolf,et al.  The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6 , 1996, The Journal of experimental medicine.

[11]  S. Nakamura,et al.  The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. , 1996, International immunology.

[12]  Austin G Smith,et al.  Essential function of LIF receptor in motor neurons , 1995, Nature.

[13]  Cannon Jg.  Cytokines in Aging and Muscle Homeostasis , 1995 .

[14]  L. Austin,et al.  In vitro myoblast to myotube transformations in the presence of leukemia inhibitory factor , 1995, Neurochemistry International.

[15]  M. Hosoi,et al.  Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats , 1995, Brain Research.

[16]  F. Cunha,et al.  Cytokine‐mediated inflammatory hyperalgesia limited by interleukin‐4 , 1995, British journal of pharmacology.

[17]  T. Hirano,et al.  Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association , 1995, The Journal of Biological Chemistry.

[18]  A. García,et al.  Lymphocyte subpopulations in patients with primary fibromyalgia. , 1994, The Journal of rheumatology.

[19]  J. Dayer,et al.  Interleukin-1, tumor necrosis factor and their specific inhibitors. , 1994, European cytokine network.

[20]  C. Dinarello,et al.  The biological properties of interleukin-1. , 1994, European cytokine network.

[21]  S. Dower,et al.  Interleukin-1 receptors. , 1994, European cytokine network.

[22]  S. Aou,et al.  Intracerebroventricular injection of interleukin-1β enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats , 1994, Brain Research.

[23]  S. Maier,et al.  Characterization of cytokine-induced hyperalgesia , 1994, Brain Research.

[24]  H. Raspe,et al.  The epidemiology of fibromyalgia. Workshop of the Standing Committee on Epidemiology European League Against Rheumatism (EULAR), Bad Säckingen, 19-21 November 1992. , 1994, British journal of rheumatology.

[25]  B. Danneskiold-Samsøe,et al.  A blinded, controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales , 1994, Acta psychiatrica Scandinavica.

[26]  P. Patterson,et al.  Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. Wolfe,et al.  Depression is not more common in rheumatoid arthritis: a 10-year longitudinal study of 6,153 patients with rheumatic disease. , 1993, The Journal of rheumatology.

[28]  A. Herz,et al.  Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. , 1993, European journal of pharmacology.

[29]  M. Yunus,et al.  Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study. , 1993, The Journal of rheumatology.

[30]  G. Yancopoulos,et al.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. , 1993, Blood.

[31]  P. Sfikakis,et al.  Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis. , 1993, Clinical immunology and immunopathology.

[32]  M. Clemens.  Polyfunctional cytokines: IL-6 and LIF (Ciba Foundation Symposium 167) : D. Metcalf (chairman), John Wiley; Chichester, 1992; x + 279 pages. £ 42.50. ISBN 0-471-93439-9 , 1993 .

[33]  F. Cunha,et al.  The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia , 1992 .

[34]  David J. Anderson,et al.  CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130 , 1992, Cell.

[35]  P. Keck,et al.  Comorbidity of fibromyalgia with medical and psychiatric disorders. , 1992, The American journal of medicine.

[36]  R. Dantzer,et al.  Mechanisms of the Behavioral Effects of Interleukin 1 Role of Prostaglandins and CRF a , 1992, Annals of the New York Academy of Sciences.

[37]  K. Raška,et al.  Cyclosporine A and prednisolone inhibit lectin- and alloantigen-induced release of sCD8: correlation with proliferative responses. , 1991, Clinical immunology and immunopathology.

[38]  N. Lahat,et al.  Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome. , 1991, Arthritis and rheumatism.

[39]  P. Tugwell,et al.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. , 1990, Arthritis and rheumatism.

[40]  H. Pope,et al.  Fibromyalgia and psychopathology: is fibromyalgia a form of "affective spectrum disorder"? , 1989, The Journal of rheumatology. Supplement.

[41]  Caro Xj.  Is there an immunologic component to the fibrositis syndrome , 1989 .

[42]  S. Ferreira,et al.  Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue , 1988, Nature.

[43]  R. Helme,et al.  Increased neurogenic inflammation in fibrositis syndrome. , 1987, The Journal of rheumatology.

[44]  D. Felson,et al.  A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. , 1986, Arthritis and rheumatism.

[45]  M. Yunus,et al.  Pathologic changes in muscle in primary fibromyalgia syndrome. , 1986, The American journal of medicine.

[46]  D. Goldenberg,et al.  Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. , 1985, The American journal of psychiatry.

[47]  M. Yunus,et al.  Muscle pathology in primary fibromyalgia syndrome: a light microscopic, histochemical and ultrastructural study. , 1984, The Journal of rheumatology.

[48]  R. Melzack.  The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.

[49]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[50]  A. Bengtsson,et al.  Dermal IgG deposits and increase of mast cells in patients with fibromyalgia--relevant findings or epiphenomena? , 1997, Scandinavian journal of rheumatology.

[51]  A. Honig,et al.  Depression : neurobiological, psychopathological, and therapeutic advances , 1997 .

[52]  H. Moldofsky.  Sleep, neuroimmune and neuroendocrine functions in fibromyalgia and chronic fatigue syndrome. , 1995, Advances in neuroimmunology.

[53]  G. Littlejohn,et al.  Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. , 1994, The Journal of rheumatology.

[54]  G. Bock,et al.  Polyfunctional cytokines : IL-6 and LIF , 1992 .

[55]  I. Russell,et al.  Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. , 1992, The Journal of rheumatology.